Abstract
Anaplastic lymphoma kinase (ALK) fusion was found in 3-7% of all patients with nonsmall cell lung cancer. The efficacy of ALK-tyrosine kinase inhibito......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
